The recently discovered antibacterial compound alaremycin produced by Streptomyces sp. A012304 structurally closely resembles 5-aminolevulinic acid, the substrate of porphobilinogen synthase.
During the initial steps of heme biosynthesis two molecules of 5-aminolevulinic acid are asymmetrically condensed to porphobilinogen. Alaremycin was found to efficiently inhibit the growth of both Gram negative and positive bacteria. Using the newly created heme-permeable E.
coli strain CSA1, we are able to uncouple heme biosynthesis from bacterial growth and demonstrate that alaremycin targets the heme biosynthetic pathway. Further studies focused on alaremycin activity against the opportunistic pathogenic bacterium Pseudomonas aeruginosa. The minimal inhibitory concentration (MIC) of alaremycin was determined to be 12 mM. Alaremycin was identified as a direct inhibitor of recombinant purified P. aeruginosa porphobilinogen synthase with a K i of 1.33 mM. To understand the molecular basis of alaremycin antibiotic activity at the atomic level, the P. aeruginosa porphobilinogen synthase was co-crystallized with the alaremycin. The crystal structure at 1.75 Å resolution reveals the antibiotic to efficiently block the active site of PBGS. The antibiotic binds as a reduced derivative of 5-acetamido-4-oxo-5-hexenoic acid. The corresponding methyl group is, however, not coordinated by any amino acid residues of the active site, excluding its functional relevance for alaremycin inhibition. Alaremycin is covalently bound by the catalytically important active site lysine residue 260 and tightly coordinated by several active site amino acids. Our data provide a solid structural basis to further improve alaremycin activity for rational drug design. Potential approaches are discussed. Modified tetrapyrroles are complex macromolecules and the most abundant pigments found in nature. Tetrapyrroles such as hemes and chlorophyll are essential prosthetic groups involved in numerous electron transport chains for energy recovery in essentially all forms of life. The biosynthetic pathway of tetrapyrroles is correspondingly highly conserved (16, 30) , making heme biosynthesis an attractive target for antibacterial drug discovery and application (24) . In fact, the tetrapyrrole biosynthetic pathway serves both as source for the production of antibiotics such as asukamycin (25) and as target for antibiotics as in the case of gabaculin (1, 19) . Recently, the antibiotic alaremycin was isolated from the culture broth of the actinomycete Streptomyces sp.
A012304. Its structure, determined to be 5-acetamido-4-oxo-5-hexenoic acid (2) (Figure 1B) , is related to 5-aminolevulinic acid (ALA), the first common precursor molecule of all tetrapyrroles.
The enzyme porphobilinogen synthase (PBGS, EC 4.2.1.24) asymmetrically condenses two such molecules of ALA to generate porphobilinogen (26, 27) (Figure 1A ). The antimicrobial activity of alaremycin against E. coli is enhanced by the presence of ALA, implying that its antimicrobial activity derives from the inhibition of PBGS (2) . During tetrapyrrole biosynthesis, four molecules of porphobilinogen are fused to generate the first tetrapyrrole uroporphyrinogen III. Thereafter the biosynthetic pathways of heme and chlorophyll separate from that of vitamin B 12 , siroheme and factor F 430 due to distinct modifications of the initial tetrapyrrole skeleton (30) .
PBGS from a range of organisms have been investigated biochemically and structurally providing indepth insights into PBGS catalysis. (4, (7) (8) (9) (10) . The two ALA substrate molecules occupy two distinct binding sites in PBGS referred to as A-and P-site to indicate that they contribute either acetic acid or propanoic acid side chains to porphobilinogen. Each ALA is covalently bound through a stable Schiff base with the lysine residues 205 and 260, respectively (12) . Although PBGS from different organisms differs with respect to the metal ion requirements and localization, the amino acid sequence is highly conserved between bacteria, archaea and eukaryotes. Whereas human PBGS is -site near the active site (9, 13 coli strain CSA1 was incubated in the presence and absence of 50 µg/mL hemin. For all strains at least 4 independent growth curves over 24 h with different alaremycin concentrations were recorded.
The MIC was determined as the lowest alaremycin concentration that inhibited growth for 5 h. Protein production and purification. Recombinant P. aeruginosa PBGS was produced and purified as described (10) . Protein integrity was analyzed by mass spectrometry and Western blot analysis. Recombinant M. barkeri PBGS was produced using E. coli strain BL21 ( Data were collected at 100 K at beamline BL1 (BESSYII, Berlin, Germany) and indexed, integrated and scaled using HKL2000 (23) . Data statistics are listed in table 3. The structure of P. aeruginosa PBGS in complex with alaremycin was solved by molecular replacement using Phaser (5) (6) and the A-chain of a related crystal (PDB code 1B4K). The structure was refined by restrained refinement with TLS-protocols (22) . For manual adjustments and quality control the graphics program Coot was used (7). Molecular depictions were prepared using PyMOL (www.pymol.org).
Atomic coordinates have been deposited with the Protein Data Bank, accession number 3B1C. barkeri. PBGS from P. aeruginosa was also used for biochemical characterization as well as for cocrystallization with alaremycin and crystal structure determination.
Heme biosynthesis is the target of alaremycin activity
E. coli laboratory strains have generally lost their ability to import heme from the surrounding medium (29) . We have created an E. coli strain capable of heme uptake by treating the hemA -E. coli strain EV61 (28), which normally requires ALA for growth, with ethylmethane sulfonate to induce chemical mutagenesis (20, 21 
Quantifying PBGS inhibition by alaremycin in cell-free extracts
As alaremycin is structurally related to ALA (the substrate of PBGS), we analyzed the effect of 0, 5 and 10 mM alaremycin on PBGS-activity in cell-free extracts of S. coelicolor, S. avermitilis, S. sp.
A012304, E. coli, B. megaterium, B. subtilis, P. aeruginosa, E. coli DH10b and E. coli CSA1.
Surprisingly, the trend of alaremycin inhibition of PBGS in cell-free extracts is distinct from that of the corresponding organisms (Table 1) . Thus 5 mM alaremycin essentially abolishes PBGS activity of B. megaterium cell-free extract, whereas S. coelicolor (22%), P. aeruginosa (25%) and B. subtilis (30%) cell-free extracts retain residual PBGS activity even at 10 mM alaremycin. Differences in alaremycin inhibition between intact organism (MIC) and cell free extracts (PBGS) activity observed for P. aeruginosa are presumably due to variable permeability and up-take capacities of individual organisms. Interestingly, Streptomyces sp. A012304 cell-free extracts retain 78% PBGS activity in the presence of 10 mM alaremycin, implying PBGS from this species to possess significant immunity against this antibiotic.
Determination of the inhibitory effect on recombinant PBGS
To unambiguously identify the molecular target of the alaremycin, we tested its effect on recombinant, purified PBGS from P. aeruginosa (metal-independent) and M. barkeri (Zn 2+ -dependent). The kinetic parameters ( Crystal structure of the P. aeruginosa PBGS-alaremycin complex P. aeruginosa PBGS was co-crystallized with alaremycin to elucidate its mode of inhibition in detail.
The structure was solved and refined to 1.75 Å resolution. The overall structure is unchanged from that of earlier reports (10, 13) , despite a change in space group from P42 1 2 (one dimer per asymmetric unit) to I422 (one monomer per asymmetric unit). Interestingly, the antibiotic is (observed in the active site of PBGS by x-ray crystallography) appears to occur during crystallization by an as yet unknown mechanism. However, the inhibitory features of the compound are not affected.
Alaremycin as lead compound for antibiotic development
An amino acid sequence alignment of PBGS from a range of bacteria demonstrates the high degree of conservation in the catalytic site. Correspondingly, amino acid residues in contact with alaremycin2 are conserved in many bacteria explaining the broad antibiotic activity of the compound. It also provides a structural basis for rational drug design to further improve its specificity and affinity. Clearly, the observed alaremycin 2 IC 50 value of 2.1 mM for the P.
aeruginosa PBGS (Table 2 ) would need to be further improved prior to any clinical applications.
Previous investigations of the catalytic mechanism of P.aeruginosa PBGS using synthetic inhibitors provide a rational basis for this (12) . These inhibitors, with a (carbon) backbone of 11 atoms, bear ether, amine, thioether, sulfoxide and sulfonyl groups at the central position 6. All were cocrystallized with P. aeruginosa PBGS. The "amine" and "thioether" derivatives revealed IC 50 values of around 0.3 mM. Their coordination by PGBS differs somewhat from that of alaremycin largely based on the fact that alaremycin is shorter than the other inhibitors. Thus, inter alia, it lacks the Asite carboxyl group. Extending alaremycin to a chain length of 11 atoms and restoring the terminal carboxyl group would be one way of increasing the overall binding affinity. As described, alaremycin is unable to utilize the second Schiff base coordination by Lys205, despite possessing a carbonyl group at position 7 positioned within 2.8 Å of the lysine amine group. The geometry is however such that a Schiff base bond would require the introduction of a carbonyl group at carbon 8 in the potentially optimized inhibitor could restore this interaction. Finally, the described synthetic amine and thioether derivatives partly serve as substrate for the enzyme, leading to C -C bond formation between C3 and C8 mirroring the ring closure via aldol addition of A-side C3 to P-side C8 MICs for bacterial growth and residual PBGS activity in cell-free extracts for alaremycin inhibition were determined as described above. PBGS activity in cell-free extracts of each strain without alaremycin was set to 100%. PBGS activity after alaremycin additions are relative values. The standard error is estimated at 10 and 15%. REFERENCES   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49 
